Publications by authors named "D Ioannides"
Article Synopsis
- Inconsistent reporting of outcomes in rosacea clinical trials is hindering accurate data analysis and meta-analyses, highlighting the need for standardized outcome measures.
- A core outcome set (COS) was developed through systematic literature reviews and a Delphi process, involving feedback from physicians and patients to identify essential outcomes in rosacea trials.
- The final COS includes 8 key domains, such as skin symptoms and patient satisfaction, which aim to enhance the comparability and relevance of future rosacea research and interventions.
Article Synopsis
- Linear IgA Dermatosis (LAD) is a rare autoimmune skin disease characterized by IgA deposits at the skin's basement membrane, affecting both children and adults with diverse clinical features.
- The European Academy of Dermatology and Venereology (EADV) developed consensus guidelines by collaborating with 29 experts across multiple countries to ensure a comprehensive approach to diagnosis and treatment.
- The resulting guidelines provide a combination of evidence-based and expert-based recommendations to aid dermatologists in effectively diagnosing and managing LAD.
: Dermatoscopy has been established as an important diagnostic tool for a wide range of skin diseases. This study aims to evaluate the use of dermatoscopy in clinical practice among Greek dermatologists. : A nationwide questionnaire-based survey was conducted collecting data on the frequency of dermatoscopic examinations, the types of lesions examined, training and educational resources, as well as factors influencing the choice to incorporate dermatoscopy into daily clinical routines.
View Article and Find Full Text PDFReal-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
Dimitrios Rigopoulos Eleftheria Tampouratzi Charalampos Angelakopoulos Zoe Apalla Ioannis Barkis Dimitrios Ioannides
J Eur Acad Dermatol Venereol
June 2024
Article Synopsis
- - The BrIDGE study examined the real-world effectiveness of brodalumab in treating moderate-to-severe plaque psoriasis in Greece, focusing on the percentage of patients achieving complete clearance (PASI100) over 24 weeks and beyond.
- - Results showed that 42% of patients reached PASI100 at Week 24, with this number increasing to 65% by Week 104, while significant improvements were noted in other assessment scores (PASI75, PASI90, and sPGA).
- - Additionally, patients reported improved quality of life, with average scores on the Dermatology Life Quality Index (DLQI) decreasing significantly over the study period, indicating better overall well-being as a result of brodalumab treatment